$ARTL
ARTELO BIOSCIENCES, INC.

2023 Q2 Form 10-Q Financial Statement

#000164033423000804 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.032M $1.057M
YoY Change -27.07% -28.68%
% of Gross Profit
Research & Development $752.0K $1.235M
YoY Change -28.79% 166.16%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.784M $2.292M
YoY Change -27.8% 17.78%
Operating Profit -$1.784M -$2.292M
YoY Change -27.8% 17.78%
Interest Expense $185.0K $124.0K
YoY Change 740.91% -752.63%
% of Operating Profit
Other Income/Expense, Net $185.0K $124.0K
YoY Change 740.91% -752.63%
Pretax Income -$1.599M -$2.168M
YoY Change -34.71% 10.33%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.599M -$2.168M
YoY Change -34.71% 10.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.56 -$0.76
COMMON SHARES
Basic Shares Outstanding 2.856M shares 2.856M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.719M $6.916M
YoY Change -70.42% -67.85%
Cash & Equivalents $5.719M $6.916M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $611.0K $903.0K
YoY Change -36.35% -16.23%
Inventory
Prepaid Expenses $903.0K
Receivables
Other Receivables
Total Short-Term Assets $14.60M $16.39M
YoY Change -34.47% -33.36%
LONG-TERM ASSETS
Property, Plant & Equipment $39.00K $50.00K
YoY Change -51.85% -31.51%
Goodwill
YoY Change
Intangibles $2.039M $2.039M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $197.0K $3.000K
YoY Change 6466.67% 0.0%
Total Long-Term Assets $2.275M $2.092M
YoY Change 7.16% -1.09%
TOTAL ASSETS
Total Short-Term Assets $14.60M $16.39M
Total Long-Term Assets $2.275M $2.092M
Total Assets $16.88M $18.48M
YoY Change -30.85% -30.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $523.0K $701.0K
YoY Change 21.06% -12.38%
Accrued Expenses $34.00K $37.00K
YoY Change -24.44% 15.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $603.0K $825.0K
YoY Change 14.42% -5.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.000K $15.00K
YoY Change -85.0% -69.39%
Total Long-Term Liabilities $6.000K $15.00K
YoY Change -85.0% -69.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $603.0K $825.0K
Total Long-Term Liabilities $6.000K $15.00K
Total Liabilities $609.0K $840.0K
YoY Change 7.41% -9.09%
SHAREHOLDERS EQUITY
Retained Earnings -$34.79M -$33.19M
YoY Change 37.22% 44.91%
Common Stock $3.000K $3.000K
YoY Change -92.86% -92.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.27M $17.64M
YoY Change
Total Liabilities & Shareholders Equity $16.88M $18.48M
YoY Change -30.85% -30.8%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$1.599M -$2.168M
YoY Change -34.71% 10.33%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.623M -$2.186M
YoY Change -17.45% 6.48%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $399.0K $2.199M
YoY Change -89.99% 755.64%
Cash From Investing Activities $399.0K $2.199M
YoY Change -89.99% 755.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.623M -$2.186M
Cash From Investing Activities 399.0K $2.199M
Cash From Financing Activities 0.000 $0.00
Net Change In Cash -1.224M $28.00K
YoY Change -164.93% -101.55%
FREE CASH FLOW
Cash From Operating Activities -$1.623M -$2.186M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
9150000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
0 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
1502000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001621221
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2855688 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2855688 shares
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38951
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ARTELO BIOSCIENCES, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-1220924
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
505 Lomas Santa Fe
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 160
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Country
EntityAddressCountry
US
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
CY2023Q1 dei City Area Code
CityAreaCode
858
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
925-7049
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
ARTL
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2855688 shares
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6916000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6888000 usd
CY2023Q1 us-gaap Marketable Securities
MarketableSecurities
8567000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1495000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
903000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
789000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
16386000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
18322000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
50000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
60000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3000 usd
CY2023Q1 us-gaap Assets
Assets
18478000 usd
CY2022Q4 us-gaap Assets
Assets
20424000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
701000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
905000 usd
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
87000 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
53000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
37000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
40000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
825000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
998000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
840000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1021000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2855688 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2855688 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51029000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
50675000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33189000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31021000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-205000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-254000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19403000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18478000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20424000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1057000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1482000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1235000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
464000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2292000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1946000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2292000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1946000 usd
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
1000 usd
CY2023Q1 artl Net Change In Fair Value Of Trading Marketable Securities
NetChangeInFairValueOfTradingMarketableSecurities
124000 usd
CY2022Q1 artl Net Change In Fair Value Of Trading Marketable Securities
NetChangeInFairValueOfTradingMarketableSecurities
-20000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
124000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2168000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1965000 usd
CY2023Q1 artl Other Comprehensive Income Loss Unrealized Gain Loss On Available For Sale Securities
OtherComprehensiveIncomeLossUnrealizedGainLossOnAvailableForSaleSecurities
29000 usd
CY2022Q1 artl Other Comprehensive Income Loss Unrealized Gain Loss On Available For Sale Securities
OtherComprehensiveIncomeLossUnrealizedGainLossOnAvailableForSaleSecurities
-22000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
20000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-24000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
49000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-46000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2119000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2011000 usd
CY2023Q1 artl Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-0.76
CY2022Q1 artl Earnings Per Share Basics And Diluted
EarningsPerShareBasicsAndDiluted
-0.70
CY2023Q1 artl Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
2856000 shares
CY2022Q1 artl Weighted Average Number Of Share Outstanding Basics And Diluted
WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
2820000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19403000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
354000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2168000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
49000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
17638000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
27167000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
624000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1965000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-46000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
25780000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2168000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1965000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
354000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
624000 usd
CY2023Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-124000 usd
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
20000 usd
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
11000 usd
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
7000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-68000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-594000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-214000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-160000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
34000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
23000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-11000 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2186000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2053000 usd
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5803000 usd
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1947000 usd
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
499000 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6490000 usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2703000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1512000 usd
CY2022Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2199000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
257000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-16000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1812000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6888000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12162000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6916000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10350000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q1 artl Non Cash Transaction Unrealized Gain Loss From Available For Sale Securities
NonCashTransactionUnrealizedGainLossFromAvailableForSaleSecurities
29000 usd
CY2022Q1 artl Non Cash Transaction Unrealized Gain Loss From Available For Sale Securities
NonCashTransactionUnrealizedGainLossFromAvailableForSaleSecurities
-22000 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ARTELO BIOSCIENCES, INC. (“we”, “us”, “our”, the “Company”) is a Nevada corporation incorporated on May 2, 2011, and based in San Diego County, California. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America (“GAAP”), and the Company’s fiscal year end is December 31.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company registered fully owned subsidiaries in Ireland, Trinity Reliant Ventures Limited, on November 11, 2016, and in the UK, Trinity Research &amp; Development Limited, on June 2, 2017. On January 8, 2020, Trinity Research and Development Limited changed its name to Artelo Biosciences Limited. The Company incorporated a wholly owned subsidiary in Canada, Artelo Biosciences Corporation, on March 18, 2020. Operations in the subsidiaries have been consolidated in the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics that target lipid-signaling pathways, including treatments intended to modulate the endocannabinoid system (the “ECS”), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Liquidity</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred losses since inception and incurred a net loss of $2,168 during the three months ended March 31, 2023. However, in November 2021, the Company completed an equity offering which generated net proceeds of $18,262. Additionally, in May 2022, the Company entered into a purchase agreement and a registration rights agreement (the “Equity Line”) with an institutional investor, providing for the sale of up to $20,000 worth of the Company’s Common Stock, over the thirty-six (36) month term of the purchase agreement. Under the terms and subject to the conditions of the purchase agreement, the Company has the right, but not the obligation, to sell to the institutional investor, and the institutional investor is obligated to purchase, up to $20,000 worth of shares of the Company’s Common Stock. As of March 31, 2023, there have been no sales under the Equity Line. The Company’s existing cash resources and the cash received from the November 2021 equity offering are expected to provide sufficient funds to carry out the Company’s planned operations into the second half of 2024. To continue operations beyond such time frame, the Company will be required to raise additional funds by completing additional equity or debt offerings or licensing our product candidates. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Negative Global or National Events</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Businesses have been and will continue to be impacted by a number of challenging global and national events and circumstances that continue to evolve, including the COVID-19 pandemic, extreme weather conditions, increased economic uncertainty, inflation, rising interest rates, recent and any potential future financial institution failures, and conflicts in Eastern Europe and in other countries. The extent of the impact of these events and circumstances on our business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and scope of the events and their impact on our development activities, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. We have been and continue to actively monitor the potential impacts that these various events and circumstances may have on our business and we take steps, where warranted, to minimize any potential negative impacts on our business resulting from these events and circumstances. The ultimate impact of these global and national events and circumstances, either individually or in aggregate, is highly uncertain and subject to change.</p>
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2168000 usd
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
18262000 usd
CY2022Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
20000000 usd
CY2023Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
20000000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6916000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6888000 usd
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q1 artl Amount In Excess Of Fdic Insurance Amount
AmountInExcessOfFdicInsuranceAmount
6300000 usd
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
8567000 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9150000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1495000 usd
CY2023Q1 us-gaap Marketable Securities
MarketableSecurities
8567000 usd
CY2023Q1 us-gaap Debt Securities Noncurrent
DebtSecuritiesNoncurrent
0 usd
CY2023Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
8567000 usd
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
9150000 usd
CY2022Q4 us-gaap Debt Securities Noncurrent
DebtSecuritiesNoncurrent
1495000 usd
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
10645000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
767760000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
612316000 shares
CY2023Q1 artl New Accounting Standard Adoptedpolicytextblock
NewAccountingStandardAdoptedpolicytextblock
<p style="font-size:10pt;font-family:times new roman;margin:0px">On January 1, 2023, the Company adopted ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. These amendments permit the use of an impairment model known as the current expected credit loss (CECL) model when assessing financial instruments for impairment. There was no impact on the Company’s financial statements as a result of the adoption of the standard.</p>
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2855688 shares
CY2023Q1 artl Intrinsic Value Of The Warrants
IntrinsicValueOfTheWarrants
0 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039000 usd

Files In Submission

Name View Source Status
artl-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001640334-23-000804-index-headers.html Edgar Link pending
0001640334-23-000804-index.html Edgar Link pending
0001640334-23-000804.txt Edgar Link pending
0001640334-23-000804-xbrl.zip Edgar Link pending
artl-20230331.xsd Edgar Link pending
artl_10q.htm Edgar Link pending
artl_ex31.htm Edgar Link pending
artl_ex311.htm Edgar Link pending
artl_ex31img1.jpg Edgar Link pending
artl_ex31img2.jpg Edgar Link pending
artl_ex31img3.jpg Edgar Link pending
artl_ex31img4.jpg Edgar Link pending
artl_ex31img5.jpg Edgar Link pending
artl_ex31img6.jpg Edgar Link pending
artl_ex31img7.jpg Edgar Link pending
artl_ex31img9.jpg Edgar Link pending
artl_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
artl-20230331_def.xml Edgar Link unprocessable
artl-20230331_pre.xml Edgar Link unprocessable
artl-20230331_cal.xml Edgar Link unprocessable
artl_10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending